BACKGROUND: DNA methylation has emerged as a promising biomarker for prostate cancer detection. In this report, we screened 36 candidate genes generated by a bioinformatic analysis of the human genome, and found that the melanoma cell adhesion molecule (MCAM) was an excellent candidate for cancer-specific methylation in prostate cancer. METHODS: Direct sequencing of bisulfite-treated genomic DNA, conventional methylation-specific PCR (MSP), real-time quantitative methylation-specific PCR, immunohistochemistry, colony formation assay, and statistical analysis. RESULTS: We found that the melanoma cell adhesion molecule (MCAM) gene promoter was specifically methylated in prostate cancer cell lines and primary prostate cancer (PCa) but not in non-neoplastic prostate (BPH) tissues by direct sequencing of bisulfite-treated genomic DNA and conventional methylation-specific PCR (MSP). Further analysis with quantitative MSP showed greater hypermethylation of the MCAM promoter (80%, 70/88) in primary prostate cancer compared to 12.5% (3/24) in BPH. Prostatic intraepithelial neoplasias (PIN), potential precursors of prostate carcinoma, showed an intermediate methylation rate of 23% (7/30). We further observed that MCAM promoter methylation was directly correlated with tumor stage (pT3+pT4) (P = 0.001) and Gleason score (P = 0.018) in primary prostate carcinoma. CONCLUSIONS: Our results suggest that MCAM promoter hypermethylation deserves further attention as a potential diagnostic prostatic DNA marker in human prostate cancer. Copyright 2008 Wiley-Liss, Inc.
BACKGROUND: DNA methylation has emerged as a promising biomarker for prostate cancer detection. In this report, we screened 36 candidate genes generated by a bioinformatic analysis of the human genome, and found that the melanoma cell adhesion molecule (MCAM) was an excellent candidate for cancer-specific methylation in prostate cancer. METHODS: Direct sequencing of bisulfite-treated genomic DNA, conventional methylation-specific PCR (MSP), real-time quantitative methylation-specific PCR, immunohistochemistry, colony formation assay, and statistical analysis. RESULTS: We found that the melanoma cell adhesion molecule (MCAM) gene promoter was specifically methylated in prostate cancer cell lines and primary prostate cancer (PCa) but not in non-neoplastic prostate (BPH) tissues by direct sequencing of bisulfite-treated genomic DNA and conventional methylation-specific PCR (MSP). Further analysis with quantitative MSP showed greater hypermethylation of the MCAM promoter (80%, 70/88) in primary prostate cancer compared to 12.5% (3/24) in BPH. Prostatic intraepithelial neoplasias (PIN), potential precursors of prostate carcinoma, showed an intermediate methylation rate of 23% (7/30). We further observed that MCAM promoter methylation was directly correlated with tumor stage (pT3+pT4) (P = 0.001) and Gleason score (P = 0.018) in primary prostate carcinoma. CONCLUSIONS: Our results suggest that MCAM promoter hypermethylation deserves further attention as a potential diagnostic prostatic DNA marker in humanprostate cancer. Copyright 2008 Wiley-Liss, Inc.
Authors: Leonel Maldonado; Mariana Brait; Myriam Loyo; Lauren Sullenberger; Kevin Wang; Sarah B Peskoe; Eli Rosenbaum; Roslyn Howard; Antoun Toubaji; Roula Albadine; George J Netto; Mohammad O Hoque; Elizabeth A Platz; David Sidransky Journal: J Urol Date: 2014-04-21 Impact factor: 7.450
Authors: R Guerrero-Preston; E Soudry; J Acero; M Orera; L Moreno-López; G Macía-Colón; A Jaffe; M Berdasco; C Ili-Gangas; P Brebi-Mieville; Y Fu; C Engstrom; R A Irizarry; M Esteller; W Westra; W Koch; J Califano; D Sidransky Journal: Cancer Prev Res (Phila) Date: 2011-05-10
Authors: J Stalin; M Nollet; P Garigue; S Fernandez; L Vivancos; A Essaadi; A Muller; R Bachelier; A Foucault-Bertaud; L Fugazza; A S Leroyer; N Bardin; B Guillet; F Dignat-George; M Blot-Chabaud Journal: Oncogene Date: 2016-04-11 Impact factor: 9.867
Authors: Kimberly Laskie Ostrow; Hannah Lui Park; Mohammad Obaidul Hoque; Myoung Sook Kim; Junwei Liu; Pedram Argani; William Westra; Wim Van Criekinge; David Sidransky Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531
Authors: Sarah C Hubbard; Michael Boyce; Cheryl T McVaugh; Donna M Peehl; Carolyn R Bertozzi Journal: Bioorg Med Chem Lett Date: 2011-05-18 Impact factor: 2.823